Medical gadget firm IDEXX Laboratories, Inc. (NASDAQ: IDXX) on Monday reported larger revenues and earnings for the third quarter of fiscal 2025.
- Third-quarter income grew 13% year-over-year to $1.11 billion; gross sales rose 12% on an natural foundation
- CAG Diagnostics recurring income elevated 11% on a reported foundation and 10% on an natural foundation
- Livestock, Poultry, and Dairy income progress was 17% on a reported foundation, and 14% organically
- Third-quarter earnings per share had been $3.40, up 21% from final 12 months; on a comparable foundation, EPS progress is 15%
- The administration raised its full-year income steering vary to $4.27-4.30 billion, or reported progress of 9.6-10.3%
- It additionally raised natural income progress steering for FY25 to eight.8-9.5%, reflecting the operational efficiency advantages
- Reported working margin outlook for the 12 months has been raised to 31.6-31.8%
- The corporate up to date its EPS outlook vary to $12.81-13.01, incorporating a $0.33 enhance at mid-point versus prior steering
